Diffuse Large B Cell Lymphoma  >>  Monjuvi (tafasitamab-cxix)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Monjuvi (tafasitamab-cxix) / Incyte
RE-MIND, NCT04150328: Lenalidomide Monotherapy in R/R DLBCL

Completed
N/A
490
Europe, US
MorphoSys AG
Diffuse Large B Cell Lymphoma
08/19
08/20
NCT04300803: Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Approved for marketing
N/A
NA
Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
MorphoSys AG, Clinigen Healthcare Ltd
DLBCL
 
 
RE-MIND2, NCT04697160: Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

Checkmark Expanded analysis data from retrospective observational RE-MIND2 study in combination with Revlimid for r/r DLBCL at ASH 2021
Dec 2021 - Dec 2021: Expanded analysis data from retrospective observational RE-MIND2 study in combination with Revlimid for r/r DLBCL at ASH 2021
Completed
N/A
3573
Europe, Canada, US, RoW
MorphoSys AG
Diffuse Large B Cell Lymphoma
05/21
05/21
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
NCT05883709: A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Not yet recruiting
N/A
15
RoW
Tafasitamab Injection, lenalidomide
Zhao Weili
Diffuse Large B-cell Lymphoma
12/23
12/24
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
N/A
100
US
Tafasitamab
Incyte Corporation, Iqvia Pty Ltd
Diffuse Large B-cell Lymphoma
10/25
08/26

Download Options